Skip to main content
. 2020 May 15;17(2):501–512. doi: 10.20892/j.issn.2095-3941.2019.0397

Figure 3.

Figure 3

Efficacy and toxicity of apatinib in stage IV oesteogenic sarcoma. (A) Overall responses of 33 patients with stage IV osteogenic sarcoma treated with apatinib. Among 33 patients, 31 had measurable lesions, and 2 patients had unmeasurable lesions. Responses at 12 weeks were PR in 2 (6.06%, 2/33), SD in 24 (72.73%, 24/33), and PD in 7 (21.21%, 7/33). (B) PFS after apatinib treatment of stage IV osteogenic sarcoma that did not respond to chemotherapy (mPFS: 7.89 months). (C) OS after apatinib treatment of stage IV osteogenic sarcoma that did not respond to chemotherapy (mOS: 17.61 months). (D) Frequencies and grades of adverse events to apatinib.